Taken together, this study indicates that GBM patients with GTR, MGMT promoter methylation, and no baseline steroid use could gain more survival benefits following immunotherapy; patients undergoing two prior recurrences may obtain more benefits from immunotherapy over non‐immunotherapy. Here, MGMT is linked to glioblastoma.